NJ State Employees Deferred Compensation Plan’s Aratana Therapeutics, Inc. PETX Stock Holding History

NJ State Employees Deferred Compensation Plan’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-110,000	Closed	-$568K	–	565
2019 Q2	$568K	Buy	110,000 +40,000	+57%	+$180K	0.1%	206
2019 Q1	$252K	Buy	70,000 +40,000	+133%	+$173K	0.05%	473
2018 Q4	$184K	Sell	30,000 -145,000	-83%	-$885K	0.04%	472
2018 Q3	$1.02M	Sell	175,000 -5,000	-3%	-$25K	0.17%	129
2018 Q2	$765K	Buy	180,000 +10,000	+6%	+$50.4K	0.14%	188
2018 Q1	$750K	Buy	170,000 +30,000	+21%	+$134K	0.13%	215
2017 Q4	$736K	Buy	+140,000	New	+$857K	0.13%	236

Other funds holding PETX

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

ASN

Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

NJ State Employees Deferred Compensation Plan's PETX Position: Q3 2019 in Review

NJ State Employees Deferred Compensation Plan sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2019, closing a stake of 110,000 shares — an estimated $568K sold.

NJ State Employees Deferred Compensation Plan first reported a position in PETX in Q4 2017 and held it in 7 quarters. The position peaked at $1.02M in Q3 2018. 2 funds tracked by Wall St. Rank hold PETX as of Q3 2019.

NJ State Employees Deferred Compensation Plan reported no remaining Aratana Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
NJ State Employees Deferred Compensation Plan sold 110,000 Aratana Therapeutics, Inc. shares in Q3 2019, an estimated $568K.
NJ State Employees Deferred Compensation Plan first reported a position in Aratana Therapeutics, Inc. in Q4 2017 and held it in 7 quarters.
NJ State Employees Deferred Compensation Plan's Aratana Therapeutics, Inc. position peaked at $1.02M in Q3 2018.
2 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2019.

Based on NJ State Employees Deferred Compensation Plan's 13F filing for Q3 2019, filed 18 Oct 2019.